Stopped: Terminated: higher rate of acute rejection in the Cyclosporin A group
New onset diabetes after renal transplantation (NODAT) is a common and severe complication negatively influencing graft and patient survival. Cyclosporine (CsA) and Tacrolimus are the basis of modern immunosuppression. Tacrolimus is superior to CsA in terms of acute rejection and graft function. However, Tacrolimus increases 2 times the risk of NODAT as compared to CsA.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Primary Outcome Measure "New Onset Diabetes After Renal Transplantation" (NODAT)
Timeframe: 1 year
Patients Treated With Insulin or Oral Antidiabetic Drugs
Timeframe: 1 year
Primary Outcome Measure (Glucose Intolerance)
Timeframe: 1 year